

3 July 2020

ASX Limited 10th Floor 20 Bridge Street Sydney NSW 2000

NEW INTERNATIONAL PATENT APPLICATION FOR BPH INVESTEE CORTICAL DYNAMICS LTD

BPH Energy Ltd (ASX:BPH) investee company Cortical Dynamics Ltd ("Cortical") is pleased to announce the filing confirmation of a new international patent application. The patent application for "Apparatus and process for measuring brain activity " has been given International (PCT) Patent Application No. PCT/AU2020/050535.

Cortical has developed an extensive patent portfolio encapsulating the BARM, providing critical patent protection across a number of key brain monitoring markets.


Corticals' competitive advantage is underpinned by a strong patent position covered by five patent families and 22 granted patents.

Currently, Cortical has patents awarded in Australia, New Zealand, Japan, the People's Republic of China, Europe and the United States.

David Breeze (Director) authorised the release of this announcement to the market. BPH has a net interest of 16% in Cortical Dynamics Ltd. (https://corticaldynamics.com/).

Authorised by

David Breeze Executive Director



About Cortical

Cortical is an Australian based medical device technology company that has developed a next generation Brain Function Monitor. The company is focused on commercialising the intellectual property developed at Swinburne University. The core-product the Brain Anaesthesia Response (BAR) monitor has been developed with the objective of better detecting the effect of anaesthetic agents on brain activity, aiding anaesthetists in keeping patients optimally anaesthetised.

The BAR monitor improves on currently used electroencephalogram (EEG) technologies by incorporating the latest advances in our understanding of how the brain's rhythmic electrical activity, the electroencephalogram (EEG), is produced. The approach used is fundamentally different from all other devices currently available in the market in that its underlying algorithm produces EEG indexes which are directly related to the physiological state of the patient's brain.

The global brain monitoring devices market is broadly segmented into three categories based on its product, application, and end-user. Fueling market growth is the various technological advancements which are leading to high functionality, lower costs, ease of operation, and miniaturization of devices.

Cortical will initially focus on the Total Intravenous Anaesthesia ("TIVA") market within Europe. TIVA provides a method of inducing and maintaining general anaesthesia without the use of any inhalation agents. The English healthcare body NICE (National Institute for Health and Care Excellence) has recommended EEG (electroencephalogram) based depth of anaesthesia monitors as options in patients receiving TIVA and in patients who are considered at higher risk of adverse outcomes during any type of general anaesthesia. This includes patients at higher risk of unintended awareness and/or excessively deep anaesthesia. It has been estimated that approximately 29 million major general surgery general anaesthesias are conducted in the EU each year of which 55% are balanced anaesthesia (using a combination of intravenous agents such as propofol and volatile gases) and 20% are total intravenous anaesthesia (TIVA) using propofol.

Cortical now has Seattle based, USA IntuitiveX ("IX") and Seoul based, Gentium Partners as shareholders. IX is a US life science accelerator, incubator and consulting service investor.